# US 2021/0275588 A1 · Biomolecule Coated Particles and Films and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275588 A1
- Document ID: US20210275588A1
- Status: Published application
- Kind: A1
- Application number: 17/258,039
- Filed: 2019-07-09
- Published: 2021-09-09
- Earliest claimed: 2018-07-10
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Tejal A. Desai; Xiao Huang; Ryan Chang; Jasper Z. Williams; Wendell A. Lim
- Web page: https://patentgrep.com/patent/US20210275588A1

## CPC

- C07K 14/55: IL-2
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 35/00: Antineoplastic agents
- C12N 5/0075: {using microcarriers}
- C12N 5/0636: {T lymphocytes}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- A61K 2039/62: {characterised by the link between antigen and carrier}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- C12N 2531/00: Microcarriers
- C12N 2533/30: Synthetic polymers
- C12N 2533/40: Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present disclosure provides polymeric particles comprising biomolecules of interest attached thereto, methods for using the same, and methods for making the same. The surface of the polymeric particles can be functionalized by attaching multiple different biomolecules of interest in a desired ratio for co-presentation. In addition, the polymeric particles may also encapsulate bio-molecules, such as, therapeutic nucleic acids, peptide and/or polypeptides for release in vivo. The present disclosure also provide synthetic particles and methods for enhancing proliferation of CAR-T cells. Additionally, the present disclosure provide biomolecule-coated films and methods.

## Claims

### Claim 1

A method of providing a first member of a specific-binding pair to a cell comprising a second member of the specific-binding pair, the method comprising:
contacting a polymeric particle with the cell, the particle comprising:
a polymeric core;
a nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently attached to a polymer, wherein the polymer is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid on a surface of the polymeric core; and
a first binding member-nucleic acid conjugate comprising a second single stranded nucleic acid covalently attached with the first binding member, wherein the second single stranded nucleic acid is complementary to the first single stranded nucleic acid and is associated with the first single stranded nucleic acid via hybridization thereby presenting the first binding member on a surface of the polymeric particle,
wherein the first binding member specifically binds to the second binding member and wherein the second binding member is present on a surface of the cell,
wherein the particle is a nanoparticle or a microparticle.

### Claim 2 (depends on 1)

The method of claim 1, wherein the polymeric core comprises poly(D,L-lactide-co-glycolide) (PLGA) or poly(lactic acid) (PLA).

### Claim 3 (depends on 1)

The method of claim 1, wherein the polymeric core comprises poly(D,L-lactide-co-glycolide) (PLGA), poly(D,L-lactide) (PLA), polyglycolic acid (PGA), poly(e-caprolactone) (PCL), or polyethylene glycol (PEG).

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the polymer of nucleic acid-polymer conjugate comprises a poly(D,L-lactide-co-glycolide) (PLGA)-polyethylene glycol (PEG) block polymer (PLGA-block-PEG) or a poly(D,L-lactide) (PLA)-polyethylene glycol (PEG) block polymer (PLA-block-PEG) or a poly(e-caprolactone) (PCL)-polyethylene glycol (PEG) block polymer (PCL-block-PEG).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the first single stranded nucleic acid comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or peptide nucleic acid (PNA).

### Claim 6 (depends on 5)

The method of claim 5, wherein the DNA or RNA or PNA comprises 5-200 bases.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the second single stranded nucleic acid comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or peptide nucleic acid (PNA), optionally wherein the DNA or RNA or PNA comprises 5-200 bases.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the first single stranded nucleic acid comprises at least 4 contiguous bases complementary to at least 4 contiguous bases in the second single stranded nucleic acid.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the cell is
i) an immune cell selected from the group consisting of a T-cell, natural killer (NK) cell, dendritic cell, macrophage, neutrophil, myeloid immune cell and B-cell, optionally wherein the immune cell has been genetically engineered, and optionally wherein the T-cell comprises regulatory T cells; or
ii) a stem cell.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the cell comprises a binding-triggered transcription switch (BTSS) comprising:
a) an extracellular domain comprising the second member of the specific-binding pair that specifically binds to the first member of the specific-binding pair;
b) a binding transducer; and
c) an intracellular domain comprising a transcriptional activator or a transcriptional repressor, wherein binding of the first member of the specific-binding pair to the second member of the specific-binding pair activates the intracellular domain.

### Claim 11 (depends on 10)

The method of claim 10, wherein the BTTS is a chimeric Notch polypeptide comprising, from N-terminus to C-terminus and in covalent linkage:
a) an extracellular domain comprising the second member of the specific-binding pair that is not naturally present in a Notch receptor polypeptide and that specifically binds to the first member of the specific-binding pair;
b) a Notch regulatory region comprising a Lin 12-Notch repeat, an S2 proteolytic cleavage site, and a transmembrane domain comprising an S3 proteolytic cleavage site;
c) an intracellular domain comprising a transcriptional activator or a transcriptional repressor that is heterologous to the Notch regulatory region and replaces a naturally-occurring intracellular Notch domain, wherein binding of the first member of the specific-binding pair to the second member of the specific-binding pair induces cleavage at the S2 and S3 proteolytic cleavage sites, thereby releasing the intracellular domain.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the first binding member or the second binding member is selected from the group consisting of: an antibody, an antibody-based recognition scaffold, a non-antibody-based recognition scaffold, an antigen, a ligand for a receptor, a receptor, a target of a non-antibody-based recognition scaffold, an extracellular matrix component and an adhesion molecule.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the first binding member comprises IL-2, such that the IL-2 is presented on the surface of the polymeric particle,
optionally wherein the second binding member is a receptor that specifically binds to the IL-2 presented on the surface of the polymeric particle.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the second binding member is a single-chain Fv (scFv) or a nanobody that specifically binds to an antigen, wherein the first binding member is the antigen.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The method of any one of claims 10-14, wherein the cell further comprises a transcriptional control element, responsive to the transcriptional activator, operably linked to a nucleotide sequence encoding a chimeric antigen receptor (CAR).

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the particle comprises a second nucleic acid-polymer conjugate comprising a third single stranded nucleic acid covalently attached to the polymer, wherein the polymer is non-covalently associated with the polymeric core thereby presenting the third single stranded nucleic acid on the surface of the polymeric core and a second first binding member-nucleic acid conjugate comprising a fourth single stranded nucleic acid covalently attached to the first binding member of a second specific-binding pair, wherein the fourth single stranded nucleic acid is complementary to the third single stranded nucleic acid and is associated with the third single stranded nucleic acid via hybridization thereby presenting the first binding member of the second specific-binding pair on a surface of the polymeric particle,
wherein the first binding member of the first specific-binding pair and the first binding member of the second specific-binding pair are present at a ratio of 10:1 to 1:10.

### Claim 17 (depends on 16)

The method of claim 16, wherein the first binding member of the second specific-binding pair is an antibody that binds to a second binding member of the second specific-binding pair expressed on cell surface of a tumor cell, wherein the method comprises contacting the cell expressing the second binding member of the first specific-binding pair and the tumor cell expressing the second binding member of the second specific-binding pair with the particle, wherein the cell expressing the second binding member of the first specific-binding pair is a T cell.

### Claim 18 (depends on 16)

The method of claim 16, wherein the first binding member of the first specific-binding pair is an antibody that binds to a second binding member of the first specific-binding pair, wherein the first binding member of the second specific-binding pair is an antibody that binds to a second binding member of the second specific-binding pair, wherein the second binding members of the first and second specific-binding pair are both expressed on the cell surface of a T-cell; and
wherein the method comprises contacting the T-cell expressing the second binding members of the first and second specific-binding pair with the particle, wherein binding of the first binding members to the second binding members of the first and second specific-binding pairs induces T-cell proliferation without significant increase in cytokine production.

### Claim 19 (depends on 18)

The method of claim 18, wherein one of the second binding members of the first or second specific-binding pairs is CD3 and the other is CD28,
optionally wherein the first binding member that binds CD3 and the first binding member that binds CD28 are present at a ratio of 1:3 to 5:1, further optionally wherein the first binding member that binds CD3 and the first binding member that binds CD28 are present at a ratio of 3:1.

### Claim 20 (depends on 15)

The method of claim 15, wherein the particle comprises a second nucleic acid-polymer conjugate comprising a third single stranded nucleic acid covalently attached to the polymer, wherein the polymer is non-covalently associated with the polymeric core thereby presenting the third single stranded nucleic acid on the surface of the polymeric core and a second first binding member-nucleic acid conjugate comprising a fourth single stranded nucleic acid covalently attached to the first binding member of a second specific-binding pair, wherein the fourth single stranded nucleic acid is complementary to the third single stranded nucleic acid and is associated with the third single stranded nucleic acid via hybridization thereby presenting the first binding member of the second specific-binding pair on a surface of the polymeric particle,
wherein the first binding member of the second specific-binding pair is an antigen that binds to CAR expressed by the cell in response to binding of the first member of the first specific-binding pair to the BTTS expressed by the cell,
wherein the cell is a T-cell and wherein binding of the CAR antigen to the T-cell induces T-cell proliferation without significant increase in cytokine production,
optionally wherein the BTTS is a chimeric Notch polypeptide.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the contacting comprises administering the particle into a tumor in a subject or intravenously.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the contacting comprises administering the cell to the subject.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the particle is a nanoparticle having a diameter ranging from 50 nm-500 nm.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the particle is a microparticle having a diameter ranging from 0.5 μm-50 μm.

### Claim 25

A polymeric particle comprising:
a polymeric core;
a nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently attached to a polymer, wherein the polymer is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid on a surface of the polymeric core; and
a first binding member-nucleic acid conjugate comprising a second single stranded nucleic acid covalently attached to the first binding member, wherein the second single stranded nucleic acid is complementary to the first single stranded nucleic acid and is associated with the first single stranded nucleic acid via hybridization thereby presenting the first binding member on a surface of the polymeric particle,
wherein the first binding member is a member of a specific-binding pair, wherein the first binding member specifically binds to a second binding member that is a member of the specific-binding pair.

### Claim 26 (depends on 25)

The polymeric particle of claim 25, wherein the first binding member is an antigen and the second binding member is an antibody that specifically binds to the antigen or vice versa.

### Claim 27 (depends on 26)

The polymeric particle of claim 26, wherein the antibody is nanobody, a single-domain antibody, a diabody, a triabody, or a minibody.

### Claim 28 (depends on 27)

The polymeric particle of claim 27, wherein the first binding member is a receptor and the second binding member is a ligand that specifically binds to the receptor or vice versa.

### Claim 29 (depends on 25, 26, 27, 28)

The polymeric particle of any one of claims 25-28, wherein the polymeric core comprises poly(D,L-lactide-co-glycolide) (PLGA) or poly(lactic acid) (PLA).

### Claim 30 (depends on 25, 26, 27, 28)

The polymeric particle of any one of claims 25-28, wherein the polymeric core comprises poly(D,L-lactide-co-glycolide) (PLGA) or poly(lactic acid) (PLA) and polyethylene glycol (PEG).

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

The polymeric particle of any one of claims 25-30, wherein the polymer of nucleic acid-polymer conjugate comprises a poly(D,L-lactide-co-glycolide) (PLGA)-polyethylene glycol (PEG) block polymer (PLGA-block-PEG) or poly(D,L-lactide) (PLA)-polyethylene glycol (PEG) block polymer (PLA-block-PEG).

### Claim 32 (depends on 25, 26, 27, 28, 29, 30, 31)

The polymeric particle of any one of claims 25-31, wherein the first single stranded nucleic acid comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or peptide nucleic acid (PNA).

### Claim 33 (depends on 32)

The polymeric particle of claim 32, wherein the DNA or RNA or PNA comprises 5-200 bases.

### Claim 34 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33)

The polymeric particle of any one of claims 25-33, wherein the second single stranded nucleic acid comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

### Claim 35 (depends on 34)

The polymeric particle of claim 34, wherein the DNA or RNA comprises 5-200 bases.

### Claim 36 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The polymeric particle of any one of claims 25-35, wherein the first single stranded nucleic acid comprises at least 4 contiguous bases complementary to at least 4 contiguous bases in the second single stranded nucleic acid.

### Claim 37 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The polymeric particle of any one of claims 25-36, wherein the polymeric particle comprises a self-peptide recognized by macrophages of a subject receiving the polymeric particle as an endogenous “do-not-eat-me” signal.

### Claim 38 (depends on 37)

The polymeric particle of claim 37, wherein the first binding member and the self-peptide are present at a ratio of ranging from 1:10 to 10:1.

### Claim 39 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The polymeric particle of any one of claims 25-38, wherein the first binding member comprises IL-2, such that the IL-2 is presented on the surface of the polymeric particle,
optionally wherein the second binding member is a receptor that specifically binds to the IL-2 presented on the surface of the polymeric particle.

### Claim 40 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The polymeric particle of any one of claims 25-38, wherein the particle comprises a second nucleic acid-polymer conjugate comprising a third single stranded nucleic acid covalently attached to the polymer, wherein the polymer is non-covalently associated with the polymeric core thereby presenting the third single stranded nucleic acid on the surface of the polymeric core and a second first binding member-nucleic acid conjugate comprising a fourth single stranded nucleic acid covalently attached to the first binding member of a second specific-binding pair, wherein the fourth single stranded nucleic acid is complementary to the third single stranded nucleic acid and is associated with the third single stranded nucleic acid via hybridization thereby presenting the first binding member of the second specific-binding pair on a surface of the polymeric particle.

### Claim 41 (depends on 40)

The polymeric particle of claim 40, wherein the first binding member of the first specific-binding pair and the first binding member of the second specific-binding pair are present at a ratio of 10:1 to 1:10.

### Claim 42 (depends on 40, 41)

The polymeric particle of claim 40 or claim 41, wherein the first binding member of the first specific-binding pair comprises an antigen that specifically binds to an antibody present in the extracellular domain of a BTTS expressed on surface of a T-cell and the first binding member of the second specific-binding pair comprises a CAR antigen that binds to CAR expressed by the T-cell in response to binding of the first binding member of the first specific-binding pair to the antibody,
optionally wherein the antibody present in the extracellular domain of the BTTS is an antibody present in the extracellular domain of a chimeric Notch polypeptide.

### Claim 43 (depends on 40, 41)

The polymeric particle of claim 40 or claim 41, wherein the first binding member of the first specific-binding pair is an antibody that binds to a first binding member of the first specific-binding pair expressed on cell surface of a T-cell, wherein the first binding member of the second specific-binding pair is an antibody that binds to a second binding member of the second specific-binding pair expressed on the cell surface of a T-cell.

### Claim 44 (depends on 43)

The polymeric particle of claim 43, wherein one of the second binding members of the first or second specific-binding pairs is CD3 and the other is CD28,
optionally wherein the first binding member that binds CD3 and the first binding member that binds CD28 are present at a ratio of 1:3 to 5:1, further optionally wherein the first binding member that binds CD3 and the first binding member that binds CD28 are present at a ratio of 3:1.

### Claim 45 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The polymeric particle of any one of claims 25-44, wherein the polymeric particles comprise nucleic acid, peptide, and/or polypeptide encapsulated in the polymeric core.

### Claim 46 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A composition comprising the polymeric particle of any one of claims 25-45 and a pharmaceutically acceptable excipient.

### Claim 47 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A kit comprising:
the polymeric particle of any one of claims 25-45; and
a cell comprising:
a BTTS, wherein the BTTS comprises:
a) an extracellular domain comprising the second member of the specific-binding pair that specifically binds to the first member of the specific-binding pair;
b) a binding-transducer; and
c) an intracellular domain comprising a transcriptional activator, wherein binding of the first member of the specific-binding pair to the second member of the specific-binding pair activates the intracellular domain; and
a transcriptional control element, responsive to the transcriptional activator, operably linked to a nucleotide sequence encoding a chimeric antigen receptor (CAR),
optionally wherein the cell is a T-cell.

### Claim 48 (depends on 47)

The kit of claim 47, wherein the BTTS comprises:
a chimeric Notch polypeptide comprising, from N-terminus to C-terminus and in covalent linkage:
a) an extracellular domain comprising the second member of the specific-binding pair that is not naturally present in a Notch receptor polypeptide and that specifically binds to the first member of the specific-binding pair;
b) a Notch regulatory region comprising a Lin 12-Notch repeat, an S2 proteolytic cleavage site, and a transmembrane domain comprising an S3 proteolytic cleavage site;
c) an intracellular domain comprising a transcriptional activator or a transcriptional repressor that is heterologous to the Notch regulatory region and replaces a naturally-occurring intracellular Notch domain, wherein binding of the first member of the specific-binding pair to the second member of the specific-binding pair induces cleavage at the S2 and S3 proteolytic cleavage sites, thereby releasing the intracellular domain.

### Claim 49

A method of making a polymeric particle, the method comprising:
covalently linking a nucleic acid to a first polymer to generate a nucleic acid-polymer conjugate, wherein the nucleic acid is a first single stranded nucleic acid;
sonicating a solution comprising the nucleic acid-polymer conjugate and a second polymer to generate polymeric particles comprising a polymeric core comprising the second polymer, wherein the polymer region of the nucleic acid-polymer conjugate is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid on a surface of the polymeric core;
attaching to the polymeric core a second single stranded nucleic acid having a sequence complementary to the first single stranded nucleic acid by hybridization; and
covalently or non-covalently attaching the second single stranded nucleic acid to a first binding member of a specific-binding pair to generate the polymeric particle.

### Claim 50 (depends on 49)

The method of claim 49, wherein the method comprises covalently attaching the second single stranded nucleic acid to the first binding member prior to attaching the second single stranded nucleic acid to the polymeric core.

### Claim 51 (depends on 49)

The method of claim 49, wherein the method comprises covalently attaching the second single stranded nucleic acid to the first binding member after attaching the second single stranded nucleic acid to the polymeric core.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49-51, wherein the second single stranded nucleic acid is attached to a linker.

### Claim 53 (depends on 49)

The method of claim 49, wherein the method comprises covalently attaching the second single stranded nucleic acid to a biotin molecule and non-covalently attaching an avidin-first binding member conjugate to the second single stranded nucleic acid.

### Claim 54 (depends on 49, 50, 51, 52, 53)

The method of any one of claims 49-53, wherein the method comprises generating a plurality of nucleic acid-polymer conjugates, wherein the plurality of nucleic acid-polymer conjugates comprises:
a first nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently linked to a first polymer molecule; and
a second nucleic acid-polymer conjugate comprising a third single stranded nucleic acid covalently linked to a first polymer molecule,
wherein the first single stranded nucleic acid and the third single stranded nucleic acid have different sequences.

### Claim 55 (depends on 54)

The method of claim 54, wherein the method comprises:
sonicating a solution comprising the plurality of nucleic acid-polymer conjugates and a second polymer to generate polymeric particles comprising a polymeric core comprising the second polymer, wherein each polymer region of the plurality of nucleic acid-polymer conjugates is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid and the third single stranded nucleic on a surface of the polymeric core;
attaching to the polymeric core:
the second single stranded nucleic acid having a sequence complementary to the first single stranded nucleic acid by hybridization and a fourth single stranded nucleic acid having a sequence complementary to the third single stranded nucleic acid by hybridization; and
covalently or non-covalently attaching:
the second single stranded nucleic acid to a first binding member of a first specific-binding pair and the fourth single stranded nucleic acid to a biomolecule to generate the polymeric particle.

### Claim 56 (depends on 55)

The method of claim 55, wherein the biomolecule is a self-peptide.

### Claim 57 (depends on 55)

The method of claim 55, wherein the biomolecule is a first binding member of a second specific-binding pair.

### Claim 58 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein the first nucleic acid-polymer conjugate and the second nucleic acid-polymer conjugate are included in the solution at a ratio of 1:10 to 10:1.

### Claim 59

A method of making a polymeric particle comprising peptide, polypeptide, and/or nucleic acid encapsulated in a polymeric core and a nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently attached to a first polymer, wherein the polymer is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid on a surface of the polymeric core, the method comprising:
sonicating a solution comprising the peptide, polypeptide, and/or nucleic acid and a second polymer;
adding the nucleic acid-polymer conjugate to the solution and further sonicating the solution to generate polymeric particles comprising a polymeric core comprising the second polymer and encapsulating the peptide, polypeptide, and/or nucleic acid,
wherein the polymer region of the nucleic acid-polymer conjugate is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid on a surface of the polymeric core;
attaching to the polymeric core a second single stranded nucleic acid having a sequence complementary to the first single stranded nucleic acid by hybridization; and
covalently or non-covalently attaching the second single stranded nucleic acid to a first binding member of a specific-binding pair to generate the polymeric particle.

### Claim 60 (depends on 59)

The method of claim 59, wherein the method comprises covalently attaching the second single stranded nucleic acid to the first binding member prior to attaching the second single stranded nucleic acid to the polymeric core.

### Claim 61 (depends on 59)

The method of claim 59, wherein the method comprises covalently attaching the second single stranded nucleic acid to the first binding member after attaching the second single stranded nucleic acid to the polymeric core.

### Claim 62 (depends on 59, 60, 61)

The method of any one of claims 59-61, wherein the second single stranded nucleic acid is attached to a linker.

### Claim 63 (depends on 59)

The method of claim 59, wherein the method comprises covalently attaching the second single stranded nucleic acid to a biotin molecule and non-covalently attaching a avidin-first binding member conjugate to the second single stranded nucleic acid.

### Claim 64 (depends on 59, 60, 61, 62, 63)

The method of any one of claims 59-63, wherein the method comprises generating a plurality of nucleic acid-polymer conjugates, wherein the plurality of nucleic acid-polymer conjugates comprises:
a first nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently linked to a first polymer molecule; and
a second nucleic acid-polymer conjugate comprising a third single stranded nucleic acid covalently linked to a first polymer molecule,
wherein the first single stranded nucleic acid and the third single stranded nucleic acid have different sequences.

### Claim 65 (depends on 64)

The method of claim 64, wherein the method comprises:
adding the plurality of nucleic acid-polymer conjugates to the solution and sonicating the solution to generate polymeric particles comprising a polymeric core comprising the second polymer and the peptide, polypeptide, and/or nucleic acid, wherein each polymer region of the plurality of nucleic acid-polymer conjugates is non-covalently associated with the polymeric core thereby presenting the first single stranded nucleic acid and the third single stranded nucleic on a surface of the polymeric core;
attaching to the polymeric core:
the second single stranded nucleic acid having a sequence complementary to the first single stranded nucleic acid by hybridization and a fourth single stranded nucleic acid having a sequence complementary to the third single stranded nucleic acid by hybridization; and
covalently or non-covalently attaching: the second single stranded nucleic acid to a first binding member of a first specific-binding pair and the fourth single stranded nucleic acid to a biomolecule to generate the polymeric particle.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the first binding member is an antigen that binds to a CAR expressed on the cell, wherein the cell is a CAR-T cell.

### Claim 67 (depends on 66)

The method of claim 66, wherein the antigen is selected from the group consisting of: CD19, HER2, epidermal growth factor receptor (EGFR), green fluorescent protein (GFP), fluorescein isothiocyanate (FITC), CD20, CD38, CD30, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), EGFRvIII, vascular endothelial growth factor receptor-2 (VEGFR2), high molecular weight-melanoma associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2, GD2, MET, GPC3, CD70, EphA2, EpCAM, CLDN18, BCMA, and CA9.

### Claim 68 (depends on 25)

The polymeric particle of claim 25, wherein the first binding member is an antigen that binds to a CAR expressed on a cell, wherein the cell is a CAR-T cell.

### Claim 69 (depends on 68)

The polymeric particle of claim 68, wherein the antigen is selected from the group consisting of: CD19, HER2, epidermal growth factor receptor (EGFR), green fluorescent protein (GFP), fluorescein isothiocyanate (FITC), CD20, CD38, CD30, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), EGFRvIII, vascular endothelial growth factor receptor-2(VEGFR2), high molecular weight-melanoma associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2, GD2, MET, GPC3, CD70, EphA2, EpCAM, CLDN18, BCMA, and CA9.

### Claim 70

A method of enhancing proliferation of a CAR-T cell, the method comprising contacting the CAR-T cell with a CAR-antigen presenting particle,
wherein the CAR-antigen presenting particle comprises a first binding member presented on a surface of a synthetic particle,
wherein the first binding member is an antigen that specifically binds to a CAR expressed on the CAR-T cell, and optionally
wherein binding of the antigen to the CAR induces proliferation of the CAR-T cell without significant increase in cytokine production and/or without CAR-T cell exhaustion.

### Claim 71 (depends on 70)

The method of claim 70, wherein the antigen is selected from the group consisting of: CD19, HER2, epidermal growth factor receptor (EGFR), green fluorescent protein (GFP), fluorescein isothiocyanate (FITC), CD20, CD38, CD30, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), EGFRvIII, vascular endothelial growth factor receptor-2 (VEGFR2), high molecular weight-melanoma associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2, GD2, MET, GPC3, CD70, EphA2, EpCAM, CLDN18, BCMA, and CA9.

### Claim 72 (depends on 70, 71)

The method of claim 70 or 71, wherein the synthetic particle is a polymeric particle, a magnetic bead, or a liposome.

### Claim 73 (depends on 68, 72)

The method of claim 72, wherein the synthetic particle is the polymeric particle set forth in claim 68.

### Claim 74 (depends on 70, 71, 72, 73)

The method of any one of claims 70-73, wherein the contacting comprises contacting a population of T cells comprising the CAR-T cell ex vivo, wherein the population of T cells have been isolated from a subject.

### Claim 75 (depends on 74)

The method of claim 74, wherein the method further comprises administering the CAR-T cell to the subject following proliferation.

### Claim 76 (depends on 70, 71, 72, 73)

The method of any one of claims 70-73, wherein contacting comprises administering the synthetic particle to the subject.

### Claim 77 (depends on 74, 75, 76)

The method of any one of claims 74-76, wherein the subject has a B-cell cancer, optionally wherein the B-cell cancer is leukemia.

### Claim 78 (depends on 77)

The method of claim 77, wherein the leukemia is relapsed or refractory CD 19+ leukemia and the antigen is CD 19.

### Claim 79 (depends on 74, 75, 76, 77, 78)

The method of any one of claims 74-78, wherein the subject has previously undergone or is undergoing CAR-T cell immunotherapy.

### Claim 80 (depends on 74, 75, 76, 77, 78, 79)

The method of any one of claims 74-79, wherein the CAR-T cell is an effector T cell that has been genetically modified to express the CAR, or wherein the CAR-T cell is a regulatory T cell (Treg) that has been genetically modified to express the CAR.

### Claim 81

A CAR-antigen presenting particle for use in a method of enhancing proliferation of a CAR-T cell in a subject, the method comprising administering a CAR-antigen presenting particle to the subject,
wherein the CAR-antigen presenting particle comprises a first binding member presented on a surface of a synthetic particle,
wherein the first binding member is an antigen that specifically binds to a CAR expressed on the CAR-T cell.

### Claim 82

A CAR-T cell for use in a method of treatment of a subject, wherein the method comprises:
contacting a CAR-antigen presenting particle with a population of T cells comprising the CAR-T cell ex vivo; and
administering the CAR-T cell to the subject following proliferation,
wherein the CAR-antigen presenting particle comprises a first binding member presented on a surface of a synthetic particle,
wherein the first binding member is an antigen that specifically binds to a CAR expressed on the CAR-T cell.

### Claim 83 (depends on 68, 81, 82)

The CAR-antigen presenting particle for use according to claim 81, or CAR-T cell for use according to claim 82, wherein the CAR-antigen presenting particle is the polymeric particle set forth in claim 68.

### Claim 84

A biomolecule-coated film comprising:
a polymeric film comprising one or more pores;
a nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently attached to a polymer, wherein the polymer is non-covalently associated with the polymeric film thereby presenting the first single stranded nucleic acid on a surface of the polymeric film; and
a first biomolecule-nucleic acid conjugate comprising a second single stranded nucleic acid covalently attached to a biomolecule, wherein the second single stranded nucleic acid is complementary to the first single stranded nucleic acid and is associated with the first single stranded nucleic acid via hybridization thereby presenting the first biomolecule on a surface of the polymeric film.

### Claim 85 (depends on 84)

The biomolecule-coated film of claim 84, wherein the polymeric film comprises polycaprolactone (PCL), poly(D,L-lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), or polyglycolic acid (PGA).

### Claim 86 (depends on 84, 85)

The biomolecule-coated film of claim 84 or claim 85, wherein the polymeric film comprises polycaprolactone (PCL) and polyethylene glycol (PEG).

### Claim 87 (depends on 84, 85, 86)

The biomolecule-coated film of any one of claims 84-86, wherein the polymer of nucleic acid-polymer conjugate comprises a polycaprolactone (PCL)-polyethylene glycol (PEG) block polymer (PCL-block-PEG), poly(D,L-lactide-co-glycolide) (PLGA)-polyethylene glycol (PEG) block polymer (PLGA-block-PEG) or poly(D,L-lactide) (PLA)-polyethylene glycol (PEG) block polymer (PLA-block-PEG).

### Claim 88 (depends on 84, 85, 86, 87)

The biomolecule-coated film of any one of claims 84-87, wherein the first single stranded nucleic acid comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or peptide nucleic acid (PNA).

### Claim 89 (depends on 88)

The biomolecule-coated film of claim 88, wherein the DNA or RNA or PNA comprises 5-200 bases.

### Claim 90 (depends on 84, 85, 86, 87, 88, 89)

The biomolecule-coated film of any one of claims 84-89, wherein the second single stranded nucleic acid comprises deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).

### Claim 91 (depends on 90)

The biomolecule-coated film of claim 90, wherein the DNA or RNA comprises 5-200 bases.

### Claim 92 (depends on 84, 85, 86, 87, 88, 89, 90, 91)

The biomolecule-coated film of any one of claims 84-91, wherein the first single stranded nucleic acid comprises at least 4 contiguous bases complementary to at least 4 contiguous bases in the second single stranded nucleic acid.

### Claim 93 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92)

The biomolecule-coated film of any one of claims 84-92, wherein the polymeric film comprises pores having a diameter of between 1 to 5 μm, optionally wherein the polymeric film comprises pores having a diameter of between 1 to 2 μm.

### Claim 94 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The biomolecule-coated film of any one of claims 84-93, wherein the polymeric film comprises a thickness of between 1 and 100 μm.

### Claim 95 (depends on 84)

The biomolecule-coated film of claim 84, wherein the biomolecule is selected from the group consisting of: a protein, a peptide, an antibody, and a nucleic acid.

### Claim 96 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The biomolecule-coated film of any one of claims 84-95, wherein the biomolecule is a first binding member presented on a surface of a synthetic particle, wherein the first binding member is an antigen that specifically binds to a CAR expressed on the CAR-T cell.

### Claim 97 (depends on 96)

The biomolecule-coated film of claim 96, wherein the antigen is selected from a group consisting of: CD19, HER2, epidermal growth factor receptor (EGFR), green fluorescent protein (GFP), fluorescein isothiocyanate (FITC), CD20, CD38, CD30, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), EGFRvIII, vascular endothelial growth factor receptor-2 (VEGFR2), high molecular weight-melanoma associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2, GD2, MET, GPC3, CD70, EphA2, EpCAM, CLDN18, BCMA, and CA9.

### Claim 98

A method of making a biomolecule coated film, the method comprising:
covalently linking a nucleic acid to a first polymer to generate a nucleic acid-polymer conjugate, wherein the nucleic acid is a first single stranded nucleic acid;
mixing a solution comprising the nucleic acid-polymer conjugate and a second polymer in a solvent;
film casting the solution to generate a polymeric film comprising the second polymer, wherein the polymer region of the nucleic acid-polymer conjugate is non-covalently associated with the polymeric film thereby presenting the first single stranded nucleic acid on a surface of the polymeric film;
attaching to the polymeric film a second single stranded nucleic acid having a sequence complementary to the first single stranded nucleic acid by hybridization; and
covalently or non-covalently attaching the second single stranded nucleic acid to a biomolecule to generate the biomolecule coated film.

### Claim 99 (depends on 98)

The method of claim 98, wherein the method comprises covalently attaching the second single stranded nucleic acid to the biomolecule prior to attaching the second single stranded nucleic acid to the polymeric film.

### Claim 100 (depends on 98)

The method of claim 98, wherein the method comprises covalently attaching the second single stranded nucleic acid to the biomolecule after attaching the second single stranded nucleic acid to the polymeric film.

### Claim 101 (depends on 98, 99, 100)

The method of any one of claims 98-100, wherein the method comprises generating a plurality of nucleic acid-polymer conjugates, wherein the plurality of nucleic acid-polymer conjugates comprises:
a first nucleic acid-polymer conjugate comprising a first single stranded nucleic acid covalently linked to a first polymer molecule; and
a second nucleic acid-polymer conjugate comprising a third single stranded nucleic acid covalently linked to a first polymer molecule,
wherein the first single stranded nucleic acid and the third single stranded nucleic acid have different sequences.

### Claim 102 (depends on 101)

The method of claim 101, wherein the method comprises:
mixing a solution comprising the plurality of nucleic acid-polymer conjugates and a second polymer prior to film casting the solution to generate polymeric film comprising the second polymer, wherein each polymer region of the plurality of nucleic acid-polymer conjugates is non-covalently associated with the polymeric film thereby presenting the first single stranded nucleic acid and the third single stranded nucleic on a surface of the polymeric film after film casting;
attaching to the polymeric film:
the second single stranded nucleic acid having a sequence complementary to the first single stranded nucleic acid by hybridization and a fourth single stranded nucleic acid having a sequence complementary to the third single stranded nucleic acid by hybridization; and
covalently or non-covalently attaching:
the second single stranded nucleic acid to a biomolecule and the fourth single stranded nucleic acid to another biomolecule to generate the biomolecule coated film.

### Claim 103 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

A method of adoptive cell transplantation, the method comprising:
encapsulating a cell or population of cells with the biomolecule-coated film of any one of claims 84-95; and
administering the encapsulated cell or encapsulated population of cells to a subject in need thereof.

### Claim 104 (depends on 96, 97)

A method of enhancing proliferation of a CAR-T cell, the method comprising contacting the CAR-T cell with the biomolecule-coated film of claim 96 or claim 97.
